OM
INSIDER · 3 COMPANIES · 10% OWNER
Opaleye Management Inc.
Every open-market transaction filed under this name, Aug 28 to Oct 16. The same name appears at more than one issuer; filings don’t say whether it’s one person.
Filings
37
37 buys · 0 sells
Bought
$6M
open market, at cost
Sold
—
includes scheduled sales
Buys since
−1.6%
avg move from buy price, 23 priced
Filings
| Traded | Ticker | Company | Role | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|---|---|
| Oct 16 | ACOG | Alpha Cognition Inc. | 10% owner | Buy | 14,283 | $8.23 | $118K | +4.2% |
| Oct 16 | GRCE | Grace Therapeutics, Inc. | 10% owner | Buy | 36,347 | $1.89 | $69K | +4.1% |
| Oct 15 | ACOG | Alpha Cognition Inc. | 10% owner | Buy | 22,657 | $8.43 | $191K | +1.8% |
| Oct 15 | GRCE | Grace Therapeutics, Inc. | 10% owner | Buy | 23,485 | $1.95 | $46K | +1.3% |
| Oct 14 | GRCE | Grace Therapeutics, Inc. | 10% owner | Buy | 11,233 | $1.93 | $22K | +1.8% |
| Oct 12 | GRCE | Grace Therapeutics, Inc. | 10% owner | Buy | 7,215 | $2.02 | $15K | −2.5% |
| Oct 9 | GRCE | Grace Therapeutics, Inc. | 10% owner | Buy | 5,340 | $2.04 | $11K | −3.6% |
| Oct 8 | GRCE | Grace Therapeutics, Inc. | 10% owner | Buy | 2,077 | $2.02 | $4K | −2.4% |
| Oct 5 | GRCE | Grace Therapeutics, Inc. | 10% owner | Buy | 1,694 | $2.06 | $3K | −4.4% |
| Oct 2 | GRCE | Grace Therapeutics, Inc. | 10% owner | Buy | 20,000 | $2.07 | $41K | −4.8% |
| Oct 1 | GRCE | Grace Therapeutics, Inc. | 10% owner | Buy | 38,796 | $2.04 | $79K | −3.2% |
| Oct 1 | ACOG | Alpha Cognition Inc. | 10% owner | Buy | 19,050 | $8.69 | $166K | −1.3% |
| Sep 29 | GRCE | Grace Therapeutics, Inc. | 10% owner | Buy | 7,849 | $2.09 | $16K | −5.7% |
| Sep 25 | ACOG | Alpha Cognition Inc. | 10% owner | Buy | 13,426 | $8.47 | $114K | +1.3% |
| Sep 24 | ACOG | Alpha Cognition Inc. | 10% owner | Buy | 18,337 | $8.57 | $157K | +0.2% |
| Sep 23 | GRCE | Grace Therapeutics, Inc. | 10% owner | Buy | 5,318 | $2.10 | $11K | −6.2% |
| Sep 21 | GRCE | Grace Therapeutics, Inc. | 10% owner | Buy | 9,771 | $2.10 | $21K | −6.2% |
| Sep 16 | ACOG | Alpha Cognition Inc. | 10% owner | Buy | 27,141 | $8.40 | $228K | +2.1% |
| Sep 16 | ACOG | Alpha Cognition Inc. | 10% owner | Buy | 53,029 | $8.57 | $455K | +0.1% |
| Sep 15 | ACOG | Alpha Cognition Inc. | 10% owner | Buy | 3,375 | $8.54 | $29K | +0.4% |
| Sep 14 | ACOG | Alpha Cognition Inc. | 10% owner | Buy | 40,373 | $8.70 | $351K | −1.3% |
| Sep 11 | SLGL | Sol-Gel Technologies Ltd. | 10% owner | Buy | 1,493 | $65.94 | $98K | — |
| Sep 10 | SLGL | Sol-Gel Technologies Ltd. | 10% owner | Buy | 1,631 | $66.80 | $109K | — |
| Sep 9 | GRCE | Grace Therapeutics, Inc. | 10% owner | Buy | 5,836 | $2.09 | $12K | −5.7% |
| Sep 9 | SLGL | Sol-Gel Technologies Ltd. | 10% owner | Buy | 3,097 | $68.70 | $213K | — |
| Sep 8 | GRCE | Grace Therapeutics, Inc. | 10% owner | Buy | 9,393 | $2.10 | $20K | −6.1% |
| Sep 8 | SLGL | Sol-Gel Technologies Ltd. | 10% owner | Buy | 471 | $69.37 | $33K | — |
| Sep 8 | SLGL | Sol-Gel Technologies Ltd. | 10% owner | Buy | 3,390 | $68.74 | $233K | — |
| Sep 4 | SLGL | Sol-Gel Technologies Ltd. | 10% owner | Buy | 2,100 | $68.98 | $145K | — |
| Sep 4 | SLGL | Sol-Gel Technologies Ltd. | 10% owner | Buy | 918 | $69.52 | $64K | — |
| Sep 2 | SLGL | Sol-Gel Technologies Ltd. | 10% owner | Buy | 900 | $68.95 | $62K | — |
| Sep 1 | SLGL | Sol-Gel Technologies Ltd. | 10% owner | Buy | 783 | $69.52 | $54K | — |
| Aug 31 | SLGL | Sol-Gel Technologies Ltd. | 10% owner | Buy | 217 | $69.10 | $15K | — |
| Aug 31 | SLGL | Sol-Gel Technologies Ltd. | 10% owner | Buy | 5,000 | $68.23 | $341K | — |
| Aug 28 | SLGL | Sol-Gel Technologies Ltd. | 10% owner | Buy | 5,000 | $68.81 | $344K | — |
| Aug 28 | SLGL | Sol-Gel Technologies Ltd. | 10% owner | Buy | 20,113 | $68.42 | $1.4M | — |
| Aug 28 | SLGL | Sol-Gel Technologies Ltd. | 10% owner | Buy | 10,000 | $71.40 | $714K | — |
"Since" is the stock's move from the filed price to the latest quote on file, not a scored call. Open-market purchases and sales only; option exercises and grants are excluded.